Every Form 4 that Idexx Laboratories Inc (IDXX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IDXX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXX filings page.
IDEXX Laboratories, Inc. (IDXX) director Lawrence D. Kingsley reported an option exercise and share sale on September 4, 2026. He exercised a non-qualified stock option for 2,203 shares of common stock at an exercise price of $114.17 per share and sold all 2,203 shares at a weighted average price of $532.0826 per share, with sale prices ranging from $531.88 to $532.14. The option, which vested in one installment on May 3, 2017, now has no remaining derivative shares reported after the exercise, and no Rule 10b5-1 trading plan is reported.
IDEXX LABORATORIES INC /DE (IDXX) reported insider equity activity by Andrew Emerson, EVP, CFO and Treasurer. On August 20, 2026, he exercised an Incentive Stock Option to acquire 265 shares of common stock at an exercise price of $178.26 per share, reducing the option balance to 925 options expiring February 13, 2028. In connection with this exercise, 86 shares of common stock were delivered or withheld to cover the exercise price or tax liability. The filing notes that his common stock holdings include 20 shares purchased under the Employee Stock Purchase Plan on March 31, 2026 and June 30, 2026.
IDEXX Laboratories director Joseph L. Hooley acquired 49 deferred stock units of common stock on July 30, 2026 under the company’s Director Deferred Compensation Plan. The grant represents $27,280.22 of deferred cash fees, converted at a closing share price of $558.80 per unit. Each unit equals one IDEXX common share, vests immediately, and will be paid in stock after his board service ends or on other preset dates allowed by the plan.
Executive Vice President George Fennell of IDEXX Laboratories reported routine equity compensation activity involving restricted stock units that vested on June 1, 2026. He acquired 639 shares of common stock through the conversion of restricted stock units, while 284 shares were disposed of to cover tax obligations. After these transactions, he directly holds 10,433 shares of common stock, reflecting a net increase in his equity position.
IDEXX Laboratories director Sophie V. Vandebroek reported equity compensation grants in the form of restricted stock units and stock options. She received 234 restricted stock units, each representing one share of common stock, and 525 non-qualified stock options with an exercise price of $533.92 per share. Both the units and options vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever comes earlier.
IDEXX Laboratories director Sam Samad received new equity awards as part of his board compensation. On May 12, 2026, he was granted 234 deferred stock units, each representing a right to one share of common stock, bringing his deferred stock unit balance to 1,354 units. He also received a non-qualified stock option for 525 shares of common stock at an exercise price of $533.92 per share, with 525 options reported as held after the grant. Both the option and deferred stock units vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs first. The deferred stock units are, by default, payable in common stock after his resignation from the board.
IDEXX Laboratories director Karen Peacock reported equity compensation awards. She received 234 deferred stock units and a non-qualified stock option covering 525 shares of common stock, both recorded as grants, not open-market purchases.
The stock option has an exercise price of $533.92 per share and expires in May 2036. Both the option and the deferred stock units vest in a single installment on the earlier of one year from grant or the 2027 annual meeting of shareholders. The deferred stock units are payable in common stock after her resignation from the board.
IDEXX Laboratories director Lawrence D. Kingsley reported multiple equity awards. On May 12, 2026, he received grants of restricted stock units covering 75 and 234 shares of common stock. Each unit represents a contingent right to receive one share.
He was also granted non-qualified stock options for 168 and 525 shares of common stock at an exercise price of $533.92 per share. According to the footnotes, these RSUs and options vest in a single installment on the one-year anniversary of the grant date or on the date of IDEXX’s 2027 annual meeting of shareholders, whichever occurs earlier. The options expire on May 11, 2036.
IDEXX Laboratories Inc. reported that director Daniel M. Junius received new equity awards. On May 12, 2026, he was granted 234 restricted stock units, each representing a contingent right to one share of common stock, and 525 non-qualified stock options with an exercise price of $533.92 per share.
According to the terms, both the options and the restricted stock units vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. Following these grants, the filing shows 234 restricted stock units and 525 options from this award held directly.
IDEXX Laboratories director Joseph L. Hooley reported new equity awards. On May 12, 2026, he received 234 deferred stock units and 525 non-qualified stock options. The options have an exercise price of $533.92 per share and expire on May 11, 2036.
Both the deferred stock units and the options vest in a single installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. The deferred stock units are generally payable in common stock after Mr. Hooley resigns from the board.
IDEXX Laboratories director Stuart Essig reported receiving equity compensation awards. He was granted 234 restricted stock units and a non-qualified stock option for 525 shares of common stock at an exercise price of $533.92 per share. Both awards vest in a single installment after about one year or on the 2027 annual shareholder meeting date, whichever comes first.
IDEXX Laboratories director Bruce L. Claflin received new equity awards as part of his board compensation. He was granted 234 deferred stock units, each representing a contingent right to receive one share of common stock, bringing his deferred stock unit balance to 1,354 units.
He was also granted 525 non-qualified stock options to buy common stock at an exercise price of $533.9200 per share, all held directly. Both the options and deferred stock units vest in one installment on the one-year anniversary of the grant date or on the date of the 2027 annual meeting of shareholders, whichever occurs earlier. The deferred stock units are, by default, payable in common stock after his resignation from the board.
IDEXX Laboratories director Irene Britt Chang reported equity awards in the form of stock options and deferred stock units. She received 525 non-qualified stock options with an exercise price of $533.92 per share and 234 deferred stock units, both as compensation grants. Following these awards, she holds 753 deferred stock units and 525 stock options directly, which vest in a single installment tied to the one-year anniversary of grant or the 2027 annual shareholder meeting.
IDEXX Laboratories director Sophie V. Vandebroek reported the vesting of restricted stock units and the resulting common share holdings. On May 7, 2026, 257 restricted stock units vested and converted into 257 shares of common stock at a stated price of $0.00 per share.
After this derivative exercise, Vandebroek directly holds 905 shares of common stock and indirectly holds 8,173 shares through the Sophie V. Vandebroek Revocable Trust. The filing shows no open-market purchases or sales, only equity compensation vesting and updated ownership totals.
IDEXX Laboratories director M. Anne Szostak increased her equity exposure through a routine equity award vesting. On May 7, 2026, restricted stock units covering 257 shares of common stock converted into 257 directly held shares at an exercise price of $0.00 per share, bringing her direct common stock holdings to 519 shares. She also reports indirect ownership of 1,542 shares held by the Trust of M. Anne Szostak and 259 shares held by The O'Hanian-Szostak Family Foundation, reflecting additional positions managed through these entities.
IDEXX Laboratories director Karen Peacock reported a routine equity compensation event. On May 7, 2026, she exercised 101 Restricted Stock Units, receiving 101 shares of common stock at an exercise price of $0.00 per share. Following this vesting and conversion, she directly holds 102 shares of common stock. No shares were sold and no tax-withholding dispositions were reported in this filing.
IDEXX Laboratories director Lawrence D. Kingsley reported the vesting and exercise of restricted stock units into common shares. On May 7, 2026, 82 and 257 restricted stock units each converted into the same number of IDEXX common shares at a stated price of $0.00 per share.
Each restricted stock unit represented a right to receive one share of common stock that vested in a single installment on May 7, 2026. The filing shows only derivative exercises and conversions, with no open-market purchases or sales. These transactions reflect compensation-related equity vesting rather than discretionary trading.
Director Daniel M. Junius of IDEXX Laboratories reported a routine equity compensation event. On May 7, 2026, a grant of 257 restricted stock units vested, converting into 257 shares of common stock. After this vesting and conversion, he directly holds 3,561 shares of IDEXX common stock.
IDEXX Laboratories director Joseph L. Hooley reported a routine equity compensation event. On May 7, 2026, 158 restricted stock units vested and were converted into 158 shares of IDEXX common stock, with no sale involved.
Following this exercise and conversion of the derivative security, Hooley directly holds 276 shares of common stock. The vested RSUs represented a contingent right to receive one share of common stock per unit, vesting in a single installment on May 7, 2026.
IDEXX Laboratories director Joseph L. Hooley acquired 43 deferred stock units tied to the company’s common stock as a compensation award. The units were valued using a reference price of $560.80 per share, reflecting the conversion of $24,375.00 of cash compensation he chose to defer.
Each deferred stock unit represents the right to receive one IDEXX share in the future. The units vest immediately and will be settled in stock after Hooley leaves the Board or on another fixed date allowed under the director plan. Following this grant, he directly holds 118 deferred stock units.
IDEXX Laboratories executive Sharon E. Underberg, EVP, GC & Corporate Secretary, exercised an incentive stock option on March 3, 2026. The option conversion resulted in 197 shares of common stock at a transaction price of 505.5300 per share, bringing her direct common stock holdings to 7,137.654 shares.
The incentive stock option right-to-buy covered 197 shares and, following the exercise, showed 0 derivative shares remaining. A footnote states the option grant to buy issuer common stock vested on February 14, 2026, indicating this was a scheduled equity award exercise.
IDEXX Laboratories Executive Vice President Nimrata Hunt sold 1,758 shares of common stock in an open-market transaction on March 3, 2026 at a weighted average price of $634.5718 per share. After this sale, Hunt directly held 18,140.944 shares and indirectly held 160 shares jointly with a spouse.
According to a footnote, the weighted average sale price reflects individual trades executed between $634.5301 and $634.8201 per share.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported corrected equity awards and updated holdings. The amended filing states that on February 12, 2026 he received a non‑qualified stock option for 13,667 shares and an incentive stock option for 162 shares, both with an exercise price equal to that day’s closing stock price.
The non‑qualified option vests in four annual installments beginning February 14, 2027, while the incentive stock option becomes exercisable in a single installment on February 14, 2030. The amendment clarifies that previously reported grants of 6,319 restricted stock units did not occur, and notes his common stock holdings include 184 vested but deferred restricted stock units.
IDEXX Laboratories President and CEO Jonathan Jay Mazelsky exercised stock options for 23,523 shares of common stock at exercise prices of $141.6000 and $505.5300. He then sold 23,326 shares in multiple open-market trades at prices including $650.6695 and $663.0439, ending with 83,803.302 shares held directly.
IDEXX Laboratories Executive Vice President Nimrata Hunt reported an open-market sale of common stock. On February 26, 2026, Hunt sold 2,693 shares at a weighted average price of $661.5413 per share in open-market transactions. After the sale, Hunt directly owned 19,898.944 common shares and indirectly owned 160 shares jointly with a spouse. A footnote explains that the sale prices ranged from $661.35 to $661.8275 per share, with detailed trade breakdowns available upon request.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported multiple stock option exercises and related share sales. On February 17, 2026 and February 19, 2026, he exercised incentive and non-qualified stock options and received IDEXX common shares.
On February 17, 2026, he then sold 5,371 shares of common stock in open-market transactions at weighted average prices ranging from about $623.28 to $629.8625 per share. After these transactions, he directly held 12,693.351 shares of IDEXX common stock, including 184 vested but deferred restricted stock units.
IDEXX Laboratories director Sophie V. Vandebroek exercised a non-qualified stock option for 945 shares of common stock on February 17, 2026 at an exercise price of $333.90 per share, converting the derivative into common stock held directly.
On the same date, she executed open-market sales of 945 and 519 common shares at weighted average prices of $628.646 and $628.56 per share, respectively. After these transactions, she held 648 IDEXX common shares directly and 8,173 shares indirectly through the Sophie V. Vandebroek Revocable Trust.
IDEXX Laboratories executive Sharon E. Underberg reported multiple equity award activities. On February 12, 2026, she received grants of 3,738 non-qualified stock options, 162 incentive stock options, and 891 restricted stock units (RSUs), with the options and RSUs vesting in scheduled installments beginning February 14, 2027 and one option grant vesting on February 14, 2030.
On February 14, 2026, several prior RSU awards vested, converting into a total of 832 shares of common stock. To cover tax obligations, 251 shares of common stock were withheld at a price of $629.35 per share. After these transactions, she directly owned 6,940.654 shares of IDEXX common stock.
Smith Martin Alexander reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 10,715 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 188 shares.
IDEXX Laboratories Executive Vice President Michael Schreck reported a series of equity compensation transactions. On February 12, 2026, he was granted 4,625 non-qualified stock options and 162 incentive stock options, along with 1,094 and 1,620 restricted stock units (RSUs), all at a stated price of 0.0000 per share. Footnotes state these options become exercisable in installments beginning February 14, 2027 and on February 14, 2030, while the RSUs vest over three or four annual installments starting February 14, 2027 and February 14, 2026.
On February 14, 2026, multiple RSU awards vested and were converted into an aggregate of 1,959 shares of common stock at a stated price of 0.0000 per share. In a separate transaction coded “F,” 876 common shares at 629.35 per share were disposed of to satisfy tax withholding, leaving 3,088.709 common shares owned directly.
MAZELSKY JONATHAN JAY reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 18,436 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 1,099 shares.
Lane Michael reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 10,810 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 1,101 shares.
IDEXX Laboratories Executive Vice President Michael Perkins Johnson reported equity award activity and related share settlements. He received stock options for 3,207 shares (non-qualified) and 162 shares (incentive) on February 12, 2026, along with 770 restricted stock units (RSUs), all at a grant price of $0.00 per share.
On February 14, 2026, 176, 179 and 218 RSUs were exercised into the same number of common shares at $0.00 per share. In a separate tax-withholding disposition, 178 common shares were delivered at $629.35 per share to cover tax obligations, leaving him with 2,794.687 directly owned common shares.
IDEXX Laboratories Executive Vice President Nimrata Hunt reported multiple equity awards, vesting events, and related share withholdings. On February 12, 2026, Hunt received grants of 4,625 non-qualified stock options, 162 incentive stock options, and restricted stock units covering 1,094 and 1,620 shares of common stock.
On February 14, 2026, several restricted stock unit awards were exercised or converted, delivering a total of 2,587 shares of common stock, while 1,154 shares were withheld at $629.35 per share to satisfy tax obligations. After these transactions, Hunt directly owned 22,591.944 shares and indirectly held 160 shares jointly with a spouse.
IDEXX Laboratories Executive Vice President George Fennell reported a series of routine equity compensation transactions. On February 12, 2026, he received grants of 3,384 non-qualified stock options, 162 incentive stock options, and 810 restricted stock units (RSUs), each representing the right to receive one share of common stock as they vest over future years.
On February 14, 2026, previously granted RSUs vested and were converted into common shares through derivative exercises, and 199 common shares were withheld at $629.35 per share to satisfy tax obligations. After these transactions, Fennell directly held 10,078 shares of IDEXX common stock.
Erickson Michael G reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 12,019 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 550 shares.
IDEXX Laboratories executive vice president, CFO and treasurer Andrew Emerson reported multiple equity compensation transactions. He exercised and converted several small lots of vested restricted stock units into common shares and had 123 shares of common stock disposed at $629.35 per share to cover tax obligations.
He also received new equity awards, including 4,270 non-qualified stock options and 162 incentive stock options, plus 729 and 284 restricted stock units. Footnotes state these options and RSUs vest in annual installments beginning on February 14, 2027, with some RSUs deferred under the company’s deferred compensation plan.
IDEXX Laboratories Executive Vice President George Fennell exercised stock options and sold shares in recent transactions. On February 9 and 10, 2026, he exercised options covering 1,476 and 11,345 shares of common stock at an exercise price of $67.85 per share.
On February 10, 2026, Fennell then sold 11,345 shares of common stock in multiple open-market transactions at weighted average prices ranging from about $642.99 to $650.32 per share. After these trades, he directly beneficially owned 9,823 shares of IDEXX common stock.
IDEXX Laboratories director Joseph L. Hooley acquired 36 deferred stock units of common stock on January 30, 2026 through the company’s Director Deferred Compensation Plan. The units were valued using a share price of $670.46, based on $24,375.00 of cash fees he elected to defer.
Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories common stock. The units vest immediately upon grant, but are only paid in shares after Hooley resigns from the board or on other fixed dates allowed under the plan. Following this grant, he beneficially owns 75 shares directly.
IDEXX Laboratories (IDXX): Executive Vice President reports option exercises and stock sales. On 11/07/2025, the officer exercised non-qualified stock options to acquire 7,125 shares at $288.78 and 5,405 shares at $505.53. The insider then sold 5,114 shares at a weighted average price of $702.2017, 1,465 shares at $703.7339, 1,468 shares at $704.8659, and 1,378 shares at $705.5448.
Following these transactions, the officer beneficially owned 21,148.9435 shares directly, plus 160 shares held indirectly jointly with spouse. Derivative holdings reported as remaining include 1,604 options. Footnotes note weighted-average sale prices with full breakdowns available upon request and prior vesting schedules for the exercised options.
IDEXX Laboratories (IDXX): Director Joseph L. Hooley reported the acquisition of 39 deferred stock units on 10/30/2025 under the company’s Director Deferred Compensation Plan, coded “A.” The filing lists a reference price of $628.54 per share and states the units were issued in exchange for deferred cash compensation of $24,375.00.
Each deferred stock unit represents a contingent right to receive one share of common stock. The units vest immediately upon grant and are payable as common stock following the director’s resignation from the Board or at other nondiscretionary dates allowed by the plan. Following the transaction, 39 shares are beneficially owned directly.